GW CEO: Cannabinoid Platform Is Growth Engine Beyond Epidiolex

Aside from epilepsy in children, GW Pharma also looking to other therapeutic spaces for testing its cannabinoid product candidates, including autism and brain cancer.

Smiling kid child holding a hemp leaf. Concepts of using marihuna for medicinal purposes for children, Medical use of non-psychoactive cannabidiol CBD
GW Hopes Its cannabidiol-based drugs will treat numerous forms of childhood epilepsy • Source: Shutterstock

With its plant-derived cannabidiol Epidiolex set to be become the first FDA-approved drug for seizures associated with rare childhood epilepsy conditions, GW Pharmaceuticals PLC is also looking to other therapeutic spaces in which to test its cannabinoid product candidates, including autism and brain cancer, the UK-based group's CEO told Scrip.

Further in the future, plant-derived cannabinoid products could offer alternatives to opioids, without the accompanying abuse danger, Justin Gover said...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.